Budesonide Orodispersible Tablets Maintain Remission in a Randomized, Placebo-Controlled Trial of Patients With Eosinophilic Esophagitis
Eosinophilic esophagitis (EoE) is a chronic inflammatory disorder. Up to 48 weeks of treatment with BOT was superior to placebo in maintaining remission of EoE. Both dosages were equally effective and well-tolerated.
